Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23005216 | 0.83 | EGLN1 (0.32) | EGLN1 | |
| SCHEMBL23005258 | 0.83 | HTR2A (0.41) | — | |
| SCHEMBL23005133 | 0.82 | CHRM2 (0.37) | EGLN1MAOBAOC3 | |
| SCHEMBL23005269 | 0.77 | PTPN11 (0.39) | — | |
| SCHEMBL18980910 | 0.73 | KIF11 (0.35) | SLC6A4HRH3EGLN1MAOBAOC3 | |
| SCHEMBL29080277 | 0.70 | KIF11 (0.40) | EGLN1MAOBAOC3 | |
| SCHEMBL23005255 | 0.70 | — | — | |
| SCHEMBL23005163 | 0.69 | — | — | |
| SCHEMBL23005168 | 0.68 | — | — | |
| SCHEMBL4596105 | 0.67 | HTR2A (0.42) | SLC6A4HRH3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174275-B2 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | DREXEL UNIVERSITY (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210054003-A1 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | DREXEL UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174275-B2 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | HSD17B7, CYP4A22, PPOX | SLC6A4 2059/4885HRH3 4643/4885EGLN1 1773/4885 |
| US-20210054003-A1 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | HSD17B7, CYP4A22, PPOX | SLC6A4 2059/4885HRH3 4643/4885EGLN1 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.